Consensus in pediatric rheumatology: Part II - Definition of clinical improvement in systemic lupus erythematosus and juvenile dermatomyositis;Consenso em reumatologia pediátrica: Parte II - Definiç ão de melhora clínica para o lúpus eritematoso sistêmico e dermatomiosite juvenil

Revista Brasileira de Reumatologia

Volumn 45, Issue 1, 2005, Pages 14-19

  Machado, Claudia ^a   Ruperto, Nicolino ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Consensus; Disease activity; Juvenile dermatomyositis; Juvenile systemic lupus erythematosus

Indexed keywords

CHILD HEALTH CARE; CLINICAL ASSESSMENT; CONSENSUS; CONSENSUS DEVELOPMENT; DERMATOMYOSITIS; DISEASE ACTIVITY; FUNCTIONAL ASSESSMENT; HUMAN; PHYSICIAN; QUALITY OF LIFE; REVIEW; RHEUMATOLOGY; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

EID: 33645452547     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI - a disease activity index for lupus patients. The committee on prognosis studies in Systemic Lupus Erythematosus. Arthritis Rheum 35:630-40, 1992.
2. Gladman D, Ginzler E, Goldsmith C, et al: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum 39: 363-9, 1996.
3. Isenberg D, Ramsey-Goldman R: Assessing patients with Lupus: towards a drug responder index. Rheumatology 38: 1045-9, 1999.
4. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P: Outcome measures to be used in clinical trials in Systemic Lupus Erythematosus. J Rheumatol 26: 490-7, 1999.
5. Ward MM, Marx AS, Barry NN: Comparison of the validity and sensitivity to change of 5 activity indices in Systemic Lupus Erythematosus. J Rheumatol 27: 664-70, 2000.
6. Brunner HI, Silverman ED, To T, Bombardier C, Feldman B: Risk factors for damage in childhood onset of Systemic Lupus Erythematosus. Cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46: 436-44, 2002.
7. Rider LG: Assessment of disease activity and its sequelae in children and adults with myositis. Curr Opin Rheumatol 8: 495-506, 1996.
8. Delbecq AL, Van De Ven AH, Gustafson DH (Ed) : Group Technique for Program Planning - a Guide to Nominal Group and Delphi processes. Glenview, Illinois. Scott, Foresman and Company, 1975.
9. Proceedings "An international Consensus Conference to define core sets of outcome measures for Juvenile Systemic lupus Erythematosus and Juvenile Dermatomyositis" Pavia, Italy Almo Collegio Borromeo March 31-April 3, 2001.
10. Ruperto N, Ravelli A, Murray KJ, et al: For the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) Preliminary Core Sets for disease damage assessment for Juvenile Systemic Lupus Erythematosus And Juvenile Dermatomyositis. Rheumatology 42: 1-8, 2003.
11. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of Systemic Lupus Erythematosus. Arthritis Rheum 25: 1271-7, 1982.
12. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of Systemic Lupus Erythematosus. Arthritis Rheum 40: 1725-6, 1997.
13. Bohan A, Peter JB: Polymyositis and dermatomyositis. N Engl J Med 292: 344-7, 1975.
14. Machado CSM, Ruperto N, Silva CHM, et al: For the Paediatric Rheumatology International Trials Organisation (PRINTO) The Brazilian version of the "Childhood Health Assessment Questionnaire - CHAQ" and the "Child Health Questionnaire - CHQ" Clin Exp Rheum (Suppl 23) 19: S25-30, 2001.
15. Brunner HI, Feldman BM, Bombardier C, Silverman ED: Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood onset Systemic Lupus Erythematosus. Arthritis Rheum 42: 1354-60, 1999.
16. Brunner HI, Silverman ED, Bombardier C, Feldman B: European consensus Lupus activity measurement is sensitive to change in disease activity in childhood onset Systemic Lupus Erythematosus. Arthritis Care Res 49: 335-41, 2003.
17. Rider LG, Feldman BM, Perez MD, et al: Development and validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I- Physician, parent and patients global assessments. Arthritis Rheum 40: 1976-83, 1997.
18. Lovell DJ, Lindsley CB, Rennenbohm RM, et al: Development and validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies - II. The Childhood Myositis Assessment Scale (CMAS): A quantitative tool for the evaluation of muscle function. Arthritis Rheum 42: 2213-9, 1999.
19. Huber AM, Feldman BM, Rennebohn RM, et al: Validation and clinical significance of the Childhood Myositis Assessment Scale (CMAS) for assessment in the Juvenile Idiopathic Myopathies. Arthritis Rheum 50: 1595-603, 2004.
20. Huber AM, Hicks JE, Lachenbruch PA, et al: Validation of the Childhood Health Assessment Questionnaire in the Juvenile Idiopathic Inflammatory Myopathies. J Rheumatol 28: 1106-11, 2001.
21. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman L: Disease activity score for children with juvenile dermatomyositis, reliability and validity evidence. Arthritis Rheum 49: 7-15, 2003.
22. Proceedings "International Consensus Conference to define core sets of outcome measures for Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis" Pavia, Italy - Almo Collegio Borromeo, March 31-April 3, 2001.
23. Smolen J, Strand V, Cardiel M, et al: Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 26: 504-7, 1999.
24. Miller FW, Rider LG, Chung Y-L, et al: For the International Myositis Outcome Assessment Collaborative Study Group Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40: 1262-73, 2001.
25. Rider L, Giannini EH, Harris-Love M, et al: For The International Myositis Assessment and Clinical Study (IMACS) Group - Defining clinical improvement in adult and juvenile myositis. J Rheumatol 30: 603-17, 2003.
26. Ruperto N, Buratti S, Duarte-Salazar C, et al: Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis Care Res. 51: 458-64, 2004.
27. Brunner EI, Giannini EH: Health related quality of life in children with rheumatic diseases. Curr Opin Rheumatol 15: 602-12, 2003.
28. Proceedings "An International Consensus Conference on Defining Improvement in Juvenile Systemic Lupus Erythematosus (JSLE) and Juvenile Dermatomyositis (JDM)- Camogli-Genoa-Italy September 27-30, 2003".